$BVS News
Last published 1w ago
- 1w agoBVSBioventus Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoBVSBioventus Reports Third Quarter Financial ResultsGlobeNewswireQ3 reported revenue of $142.4 million increased 3%Q3 GAAP earnings of $0.08 per diluted share compared to the prior-year period earnings of $0.05 per diluted shareNon-GAAP earnings* of $0.17 per diluted share compared
- 1w agoBVSThird Quarter 2026 Earnings Conference Call - BIOVENTUS INCEarnings Call TranscriptsGood afternoon, and welcome to the BioVentus Third Quarter 2026 Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star t
- 2w agoBVSBioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026GlobeNewswireDURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report
- 3mo agoBVSBioventus Inc. Second Quarter 2026 Earnings Conference Call - BIOVENTUS INCEarnings Call TranscriptsHello and thank you for standing by. My name is Regina and I will be your conference operator today. At this time, I'd like to welcome everyone to the BioVentus, Inc. Second Quarter 2026 Earnings Conference Call. All lin
- 3mo agoBVSBioventus Inc. Second Quarter 2026 Earnings Conference Call - BIOVENTUS INCEarnings Call TranscriptsHello and thank you for standing by. My name is Regina and I will be your conference operator today. At this time, I'd like to welcome everyone to the BioVentus, Inc. Second Quarter 2026 Earnings Conference Call. All lin
- 3mo agoBVSBioventus Reports Second Quarter Financial ResultsGlobeNewswireQ2 reported revenue of $153.2 million increased 4%Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted shareNon-GAAP earnings* of $0.22 per diluted share compared
- 3mo agoBVSBioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026GlobeNewswireDURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report
- 5mo agoCNXUIARTBVSORGO+1The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement PartsPR NewswireFor more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't...
- 5mo agoBVSBioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare ConferenceGlobeNewswireDURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial
- 5mo agoCNXUIARTEOLSBVS+1Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItPR NewswireUSA News Group News Commentary — Wall Street's regenerative medicine bench just got one name deeper. On May 21, 2026, Conexeu Sciences Inc. (Nasdaq:...
- 6mo agoBVSBioventus Reports First Quarter Financial ResultsGlobeNewswireQ1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15 per diluted share
- 6mo agoACRXANIKAXGNBEAT+6TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesGlobeNewswireMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a
- 6mo agoBVSBioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026GlobeNewswireDURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for
- 8mo agoBVSBioventus Inc. Fourth Quarter 2025 Earnings Conference Call - BIOVENTUS INCEarnings Call TranscriptsGood day, and welcome to the BioVentus fourth quarter 2025 earnings conference call. All participants will be in a listen-only mode. Should you need assistance, please signal conference specialists by pressing the star k
- 8mo agoBVSBioventus Announces Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireQ4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0%Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year periodNon-GAAP earnings* of
- 8mo agoBVSBioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026GlobeNewswireDURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for
- 11mo agoBVSBioventus to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireDURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will
- 1y agoBVSBioventus Inc. Third Quarter 2025 Earnings Conference Call - BIOVENTUS INCEarnings Call TranscriptsGood day, and welcome to the BioVentus, Inc. 3rd Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star
- 1y agoBVSBioventus Reports Third Quarter Financial ResultsGlobeNewswireQ3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8%Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per
- 1y agoBVSBioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025GlobeNewswireDURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for
- 1y agoBVSBioventus Inc. (BVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoBVSBioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferenceGlobeNewswireDURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial
- 1y agoBVSBioventus to Present at the Canaccord Genuity 45th Annual Global Growth ConferenceGlobeNewswireDURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will
- 1y agoBVSBioventus Inc. (BVS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoBVSBioventus Reports Second Quarter Financial ResultsGlobeNewswireQ2 reported revenue of $147.7 million declined 2.4%; Organic* revenue advanced 6.2%Second quarter diluted earnings per share was $0.11 compared to a diluted loss per share of $0.40 in the prior-year periodNon-GAAP
- 1y agoBVSBioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased LiquidityGlobeNewswireDURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has entered into a $400 million
- 1y agoBVSBioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation ProductsGlobeNewswireDURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA)
- 1y agoBVSBioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025GlobeNewswireDURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for
- 1y agoBVSBioventus Reports First Quarter Financial ResultsGlobeNewswireQ1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0%First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-year periodNon-GAAP earnings* of $0.08 per
- 1y agoBVSBioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025GlobeNewswireDURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for
- 1y agoBVSBioventus Announces Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireAccelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from operations of $19.3 million increased 86.3%Provides
- 1y agoBVSBioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025GlobeNewswireDURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for
- 1y agoBVSBioventus to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireDURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd
- 1y agoBVSBioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed PartnersGlobeNewswireDURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, announced today that it has successfully completed the
- 2y agoBVSBioventus Inc. (BVS) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBVSBioventus Reports Third Quarter Financial ResultsGlobeNewswireQ3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* GrowthQ3 Gross Margin Expanded 200 bpsQ3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to Previous Year
- 2y agoBVSBioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024GlobeNewswireDURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for
- 2y agoBVSBioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed PartnersGlobeNewswireDURHAM, N.C., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, announced today that it has signed a definitive agreement
- 2y agoBVSBioventus Inc. (BVS) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBVSBioventus to Present at the Canaccord Genuity 44th Annual Global Growth ConferenceGlobeNewswireDURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer,
- 2y agoBVSBioventus Reports Second Quarter Financial ResultsGlobeNewswireQ2 Revenue Advanced by 10.3%, Organic Growth* by 13.9%Q2 Gross Margin Expanded 350 bps and Adjusted Gross Margin* 180 bpsCash from Operations of $15.2 million Increased 40.5%Raising Full-Year 2024 Financial
- 2y agoBVSBioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024GlobeNewswireDURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for
- 2y agoAPYXBVSMDNCXTNTApyx Medical Corporation Announces Board Leadership TransitionBusiness WireAndrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx
- 2y agoBVSBioventus, Inc. (BVS) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBVSBioventus Reports First Quarter Financial ResultsGlobeNewswireRaises Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic PrioritiesAccelerated First Quarter Revenue Growth by 8.7%, Organic Growth* by 15.3%Gross Margin Expanded
- 2y agoBVSBioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024GlobeNewswireDURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for
- 2y agoBVSBioventus Inc. (BVS) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBVSBioventus Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireAccelerated fourth quarter sales growth to 7.6%, organic growth* of 14.3%Appointed Rob Claypoole as President and Chief Executive Officer, bringing more than 20 years of leadership experience in the global medical
- 2y agoBVSBioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024GlobeNewswireDURHAM, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for